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episodes), condition speciﬁc quality of life (Incontinence Quality
of Life Questionnaire (I-QOL)), and SF-6D preference scores were
measured at enrollment and 24weeks after treatmentwith a single
injection of botulinum toxin type A or placebo. We measured the
correlation between SF-6D, I-QOL and UI episode change scores.
We used multiple linear regressions to estimate the impact on
SF-6D scores of 50%; 50%–99% and 100% reductions in UI
episodes and a 10-point improvement in I-QOL. These thresholds
are thought to be clinically signiﬁcant and are often reported as
trial outcomes. RESULTS: SF-6D change scores between enroll-
ment and 24 weeks were moderately correlated with I-QOL
change scores (rho = 0.41; p < 0.01) but non-signiﬁcantly corre-
lated with UI episode changes scores (rho = -0.19; p = 0.20). At
24weeks, mean (95%CI) daily UI episodes fell by 0.85 (0.04, 1.3)
and mean I-QOL scores improved by 18 (12, 24). SF-6D scores
increased by 0.03 (0.003, 0.058), due, primarily, to improvements
in the role limitations domains. A50% reduction in UI episodes
was achieved by 49% of patients and corresponded to a 0.09
(0.02, 0.16) SF-6D increase. A  10-point increase in I-QOL was
attained by 65% of patients and was associated with a 0.05
(-0.02, 0.12) SF-6D increase. CONCLUSIONS: These estimates
provide preliminary data for decision analysts wishing to map UI
outcomes to preference scores. The results demonstrate that clini-
cally important changes in condition speciﬁc quality of life are
reﬂected in SF-6D preference scores.
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OBJECTIVES: A randomized clinical trial (TIMES) demon-
strated that combination therapy with tolterodine extended
release (ER) plus tamsulosin for 12 weeks provides clinical ben-
eﬁts over monotherapy with either agent or placebo in men with
moderate to severe lower urinary tract symptoms (LUTS) and
overactive bladder. However, the TIMES study did not report
the impact of these therapies on utility. We developed a statisti-
cal model to predict the utility and quality-adjusted life-years
(QALYs) associated with the various TIMES therapies.
METHODS: The statistical model was developed using urinary
tract symptoms and quality of life (SF-12) data collected from
9416 males participating as part of a separate epidemiologic
survey (EpiLUTS). The model was a multinomial regression,
which predicted the level of responses to each of the 12 domains
of the SF-12. The predictors were daytime and nighttime urinary
frequency, urgency episodes, urge incontinence and International
Prostate Symptom Scores (IPSS). This regression was then used
to predict SF-12 scores of the TIMES patients, based on the
observed mean symptoms values in this study. Next, based on
published regression algorithms, these predicted SF-12 answers
were transformed into EQ-5D utility scores, from which QALYs
were calculated. RESULTS: IPSS score and number of urgency
episodes in 24 hours had the strongest impact on overall utility,
whereas nighttime and especially daytime micturition frequency
had less impact. At week 12, utility scores for placebo, toltero-
dine monotherapy, tamsulosin monotherapy, and combination
therapy were 0.657, 0.684, 0.679 and 0.701, respectively. Cor-
responding QALYs over 12 weeks were 0.143, 0.146, 0.146 and
0.148. Thus, combination therapy resulted in the highest incre-
mental QALYs, saving 0.005 QALYs vs. placebo, 0.002 vs.
tolterodine, and 0.003 vs. tamsulosin. CONCLUSIONS: Com-
bination therapy with tolterodine ER plus tamsulosin results in
the highest predicted utility and QALY gains compared to
placebo or monotherapy with either agent.
PUK18
VALIDATION OFTHE URINARY SENSATION SCALE (USS)
Coyne KS1, Margolis MK1, Jumadilova Z2,Vats V2, Hsieh R1
1United BioSource Corporation, Bethesda, MD, USA, 2Pﬁzer Inc, New
York, NY, USA
OBJECTIVES: To assess the validity of the Urinary Sensation
Scale (USS) in women with overactive bladder (OAB) and men
with OAB and prostate symptoms (OAB-BPH). METHODS:
Data from 2 clinical trials of tolterodine treatment for OAB were
used to assess the validity of the USS, a 5-point rating scale to
assess the amount of urinary urgency associated with each uri-
nation. The USS ranges from “No feeling of urgency: I could
continue activities until I chose to use the bathroom” to “Unable
to hold; leak urine: I had a wetting accident before arriving at the
bathroom.” The USS was administered with a daily bladder diary
in the 2 trials. Two methods to evaluate the USS are to calculate
a mean urgency score (Mean USS) of all voids or to sum all
urgency ratings (Sum USS). Concurrent validity, discriminant
validity, and responsiveness of the USS were assessed. RESULTS:
Data from 580 men (Trial 1) and 331 women (Trial 2) were
analyzed. Mean age was 65.2 (men) and 47.8 (women); in both
studies, 70% were Caucasian. Correlations of USS scores with
bladder diary variables were small to moderate and higher
among Sum USS than Mean USS. Correlations among the USS
with OAB-q, Perception of Bladder Condition (PBC), and Per-
ception of Treatment Beneﬁt (PTB) were moderate to strong and
higher with Sum USS. Both the Mean and Sum USS signiﬁcantly
discriminated (all p < 0.001) among all bladder diary variables
(except men, nocturia and UUI) when grouped as improved/not
improved as well as by the OAB-q, PBC, and PTB. Effect sizes for
men and women respectively were -0.52 and -1.09 for Mean
USS and -0.72 and -1.36 for Sum USS. CONCLUSIONS: The
USS is a valid and highly responsive measure of urinary urgency
in women with OAB and men with OAB-BPH.
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OBJECTIVES: To evaluate the psychometric properties of 10
language versions of the King’s Health Questionnaire (KHQ).
METHODS: The KHQ, a 21-item instrument to assess health-
related quality of life in patients with urinary incontinence and
OAB, has been translated into numerous languages. Data from
a multicenter, randomized, double-blind, placebo- and active-
controlled trial of fesoterodine for OAB patients were analyzed to
assess the psychometric properties of the KHQ in ten languages.
Patients completed the KHQ at Baseline (BL) and Week 12 of
treatment and bladder diaries for 3 days before each visit. Mean
BL scores, Cronbach alphas, and subscale change scores were
calculated for the KHQ in each language. RESULTS: Data from
839 patients were analyzed (Australia = 104; Bulgaria = 58;
Czech Republic = 55; Estonia = 59; Germany = 59; New Zealand
(NZ) = 82; Poland = 84; Romania = 66; Russia = 81; and South
Africa = 191). Mean age was 56.7  13.9 years; 80% were
female; 96% were white. BL subscale scores ranged from 16.8
(General Health Perceptions [GHP]; NZ English) to 83.6 (Impact
on Life; German). Six of 7 multi-item KHQ subscales (Role
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